Baxter Q2 Sales Rise 5% Organic, Raises Full-Year EPS Guidance to $1.95-$2.15
BAX sits 67% above its 52-week low of $15.73 on elevated volume (3.2× avg).
Summary
Baxter International reported Q2 2026 sales of $2.96B (up 5% organic) and adjusted EPS of $0.56, beating expectations and raising full-year guidance. The quarter included a segment realignment, an IRS settlement, and tariff refunds, but the Novum LVP pump hold continues.
Key Events · Earnings and Guidance · BAX
-
Q2 Beat and Raise
Sales of $2.96B grew 5% organically; adjusted EPS of $0.56 beat consensus. Full-year adjusted EPS guidance raised to $1.95-$2.15.
-
Segment Realignment
Consolidated from three to two segments: Medical Products & Therapies and Healthcare Systems & Technologies. Prior periods recast.
-
IRS Settlement
Settled 2019-2020 transfer pricing audit for amounts consistent with existing reserves; no adjustment to 2021-2025 reserves.
-
Tariff Refund Boost
Recorded ~$75M in IEEPA tariff refunds in Q2, with $65M receivable. Additional refund claims expected but not material.
Analysis · BAX · Industrial Applications And Services
Baxter delivered a clean Q2 beat with $2.96B in sales (up 5% organic) and adjusted EPS of $0.56, well above consensus. The company raised its full-year adjusted EPS guidance to $1.95-$2.15, signaling confidence in the turnaround. The quarter also saw a segment realignment, an IRS settlement with no cash impact, and a $75M tariff refund boost. However, the Novum LVP pump remains under a shipment hold, and credit rating agencies have negative outlooks. The results show operational momentum but also highlight lingering regulatory and balance-sheet risks.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1498 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BAX was trading at $26.25 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $13.8B. The 52-week trading range was $15.73 to $30.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.